GH-releasing peptide

Hexarelin

Hexarelin is a synthetic growth hormone-releasing hexapeptide2,3; the app lists a half-life of about 1 hour, and WADA names it as examorelin (hexarelin) in prohibited class S2.1

Moderate evidenceGet the app

Level after one dose

Hexarelin after one dose: 50% at ~1 h, 25% at 2 h, 12.5% at 3 h.

Drawn from the half-life in the app's model, ~1 h. The model's figures

Hexarelin, also named examorelin, is a synthetic hexapeptide with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 that stimulates the release of growth hormone (GH).2,3,1 A search of PubMed on 16 November 2026 for hexarelin in the title or summary text returned 291 records, and 58 of them carry the publication type randomized controlled trial or clinical trial. ClinicalTrials.gov returned 0 studies for the term hexarelin on 16 November 2026. A 2018 review of growth hormone secretagogues by Sigalos and Pastuszak states that "few long-term, rigorously controlled studies have examined the efficacy and safety of GHSs", a statement about the class and not about hexarelin alone.4 The app grades the evidence for hexarelin as moderate, a grade that is the app's own and not a rating from the studies cited.

In people

In 12 healthy young volunteers, GH release after 1 microgram/kg of intravenous hexarelin was about 2 times that after 1 microgram/kg of GHRH (P < 0.001), and the response to 2 micrograms/kg was reproducible on repeat testing.2 In healthy men, Massoud and colleagues reported that intravenous hexarelin raised GH to a plateau at 1.0 microgram/kg with an ED50 of 0.48 ± 0.02 microgram/kg, and raised prolactin with an ED50 of 0.39 ± 0.02 microgram/kg, with cortisol rising in a step to about 40% at 0.5 microgram/kg.5 The same authors gave 0.125 microgram/kg of hexarelin with 1.0 microgram/kg of GHRH and wrote that "Low dose hexarelin was synergistic with GHRH".5 In another 1996 study, 6 men were given two boluses of 1 microgram/kg of hexarelin, GHRH or both; a second hexarelin bolus still released significant GH (P = 0.02 against saline), with lower peak GH secretion rates at 120 minutes (P = 0.03) but not at 60 minutes, and Massoud and colleagues concluded that the synergism is "a property which is lost after repeated administration".6 Loche and colleagues tested 15 children and 4 adults with GH deficiency: in the 8 with idiopathic deficiency the GH response was similar to that of 45 short normal children, and the authors wrote that "the inability of Hex to stimulate GH secretion in patients with hypothalamic-pituitary disconnection strongly supports the concept that in humans, the GH-releasing effect of GH-releasing peptides is mediated by the hypothalamus".7 The app's note says hexarelin produces the strongest acute GH release among GHRPs; in 6 normal young adults, Arvat and colleagues reported that 1 microgram/kg of intravenous GHRP-2 and hexarelin "induced a similar, strong GH response", and that both peptides "induce similar increases in PRL, ACTH and cortisol levels".8

In cells and animals

A 2014 review by Mao, Tokudome and Kishimoto states that hexarelin "can bind to and activate the growth hormone secretagogue receptor (GHSR) in the brain similar to its natural analog ghrelin".9 In rat cardiac membranes, Bodart and colleagues identified the hexarelin binding protein as CD36, and in perfused hearts hexarelin raised coronary perfusion pressure in a dose-dependent manner, an effect lacking in hearts from CD36-null mice.10 In Chinese hamster ovary cells expressing the human GH secretagogue receptor, Orkin and colleagues reported "marked desensitisation of the calcium response to hexarelin" 2 to 5 minutes after the first dose.11

3

Pharmacokinetics

Values from the Milligram app's model.

Half-life
~1 h
Bioavailability
95%
Typical dose
100–200 mcg/day
Route
SubQ
Time to peak
~15 min

The table sets figures from studies beside the app's half-life, time to peak and bioavailability for subcutaneous hexarelin.

Table 3.1Pharmacokinetics3 rows
ParameterAppReported in studies
Half-life~1 hIn 12 men given 0.5, 1 and 2 micrograms/kg intravenously, plasma GH fell to baseline within 240 min "with a half-life of about 55 min", which is the half-life of the GH response.3 After 1 microgram/kg intravenously in dogs (number not stated in the record), hexarelin's terminal half-life was 120 min.12 In male rats given 5 micrograms/kg intravenously it was 75.9 ± 9.3 min (spread not defined in the record).13
Bioavailability95%Biological bioavailabilities, estimated from GH levels in 12 healthy young volunteers, were 77.0 ± 10.5% subcutaneous, 4.8 ± 0.9% intranasal and 0.3 ± 0.1% oral.2,14 In rats, subcutaneous bioavailability was 64%.13
Time to peak~15 minThese are times of peak GH response, not of hexarelin concentration. After intravenous hexarelin, plasma GH peaked at about 30 min.3 In a study of 10 children with familial short stature and 2 adults with GH deficiency, peak GH in the intravenous test occurred at 15 to 30 minutes and in the intranasal test between 30 and 60 minutes, and the 2 adults with GH deficiency showed no GH response.15

The chart uses the app's half-life of about 1 hour and time to peak of about 15 minutes, and the interval shown as studied is twice-daily subcutaneous injection for 16 weeks, as in Rahim and colleagues, 1998.16

Level over 3 days

Interval between doses

Level, as a share of the peak after one 100 mcg dose

As studied: twice daily16.

An illustration from a pharmacokinetic model using a half-life of 1 hours. It is not a measured level or a suggested dose.

4

Human studies

Most of the studies below measured hormone responses, Laron and colleagues and Klinger and colleagues also measured growth velocity in children,17,18 and three groups measured left ventricular ejection fraction (LVEF).19,23,25

Table 4.1Human studies8 rows
Study and yearDesignPeopleDose and lengthMain result
Ghigo and colleagues, 19942Single doses by four routes, with intravenous saline and GHRH as references; no sponsor named in the PubMed record12 healthy young volunteersIntravenous 1 and 2 micrograms/kg; subcutaneous 1.5 and 3 micrograms/kg; intranasal 20 micrograms/kg; oral 20 and 40 mgGH area under the curve 3175 ± 506 micrograms/min.L at 1 microgram/kg intravenous against 1544 ± 161 for GHRH (P < 0.001)
Imbimbo and colleagues, 19943Double-blind, placebo-controlled, rising dose; the first author's affiliation is the Medical Department of Mediolanum Farmaceutici, Milan12 adult male volunteersSingle intravenous boluses of 0.5, 1 and 2 micrograms/kg, and placeboPeak GH 26.9, 52.3 and 55.0 ng/ml at 0.5, 1 and 2 micrograms/kg against 3.9 with placebo; GH back to baseline within 240 min
Maccario and colleagues, 200220Two or three daily subcutaneous injections, 24-hour sampling every 20 min, intravenous test at the end; no sponsor named in the PubMed record6 normal young men1.5 micrograms/kg subcutaneously two or three times in 24 hours; 1 microgram/kg intravenously at the endMean 24-hour GH rose equally with two and three injections; IGF-I, prolactin, ACTH and cortisol secretion did not change; the intravenous test then gave a blunted GH response and an abolished ACTH and cortisol response
Rahim and colleagues, 199816,21Twice-daily subcutaneous hexarelin for 16 weeks, with a hexarelin challenge at weeks 0, 1, 4, 16 and 20; no sponsor named in the PubMed record12 healthy elderly people1.5 micrograms/kg subcutaneously twice daily for 16 weeksGH area under the curve 19.1 ± 2.4 micrograms/L.h at week 0, 10.5 ± 1.8 at week 16 (P < 0.01) and 19.4 ± 3.7 at week 20; IGF-I and IGFBP-3 did not change significantly, and of the bone markers only C-terminal propeptide of type I collagen was higher at week 16 (P = 0.019)
Laron and colleagues, 199517Intranasal hexarelin for up to 8 months; no comparison group described in the PubMed record8 prepubertal short children aged 4 to 11.6 years60 micrograms/kg intranasally three times daily, up to 8 monthsIGF-I rose from 10.4 ± 3.9 to 14.1 ± 4.6 nmol/l (P < 0.004); growth velocity rose from 5.3 ± 0.8 to 8.3 ± 1.7 cm/year (P < 0.0001)
Klinger and colleagues, 199618Prospective, with hexarelin tests before, during and after treatment; no comparison group described in the PubMed record7 prepubertal constitutionally short children, mean age 7.6 ± 2.4 years60 micrograms/kg intranasally three times daily, 6 to 10 monthsPeak GH to an intranasal test dose fell from 70.6 ± 28.2 to 34.1 ± 15.7 mU/l after 7 days (P < 0.002); growth velocity rose from 5.3 ± 0.9 to 7.4 ± 1.6 cm/year (P < 0.005)
Ghigo and colleagues, 199622Two treatment studies, intranasal and oral, with GH tests before and after; no comparison group described in the PubMed recordStudy I: 7 elderly people aged 67 to 80; study II: 7 elderly women aged 63 to 80Intranasal 1.25 mg (about 18 micrograms/kg) three times daily for 8 days; oral 20 mg (about 300 micrograms/kg) three times daily for 15 daysGH response not significantly higher than to intravenous GHRH and maintained after both (with a trend towards increase after intranasal); IGF-I unchanged with intranasal and 141.6 ± 13.6 to 156.0 ± 10.7 micrograms/l with oral (P < 0.03); IGFBP-3 1.6 ± 0.2 to 2.4 ± 0.2 mg/l intranasal (p < 0.02) and 3.1 ± 0.2 to 3.4 ± 0.2 oral (p < 0.03); no side effect, no prolactin or cortisol change
Broglio and colleagues, 200223Intravenous hexarelin compared with GHRH, recombinant human GH and placebo during bypass surgery under general anesthesia; no sponsor named in the PubMed record24 male patients with coronary artery disease, mean age 59.5 ± 1.1 years, given hexarelin, GHRH, rhGH or placebo (number per group not given in the PubMed record)Hexarelin 2.0 micrograms/kg intravenously, acute administration; comparators GHRH 2.0 micrograms/kg, rhGH 10.0 micrograms/kg, placeboLVEF, cardiac index and cardiac output rose from 10 min and lasted up to 90 min (P < 0.001 each), wedge pressure fell (P < 0.01) and mean arterial pressure rose (P < 0.05), with no change in left ventricular end diastolic volume or systemic vascular resistance index and a transient fall in central venous pressure (P < 0.05 at 30 min only); GHRH, rhGH and placebo had no hemodynamic effect

Deeper analysis: Ghigo and colleagues, 1994

Ghigo and colleagues at the University of Turin measured GH in 12 healthy young volunteers after four routes of hexarelin.2 The authors wrote that "the GH-releasing activity appeared to be dose dependent".2 The PubMed record names no sponsor and states no limitations of the study.

Deeper analysis: Rahim and colleagues, 1998 and 1999

Rahim, O'Neill and Shalet at Christie Hospital, Manchester, tested the GH response to a single injection at weeks 0, 1, 4, 16 and 20 of the 16-week course.16 GH area under the curve fell at week 4 (12.3 ± 2.4 micrograms/L.h, P < 0.05) and week 16 (P < 0.01) and was 19.4 ± 3.7 at week 20, four weeks after therapy ended, and the authors described "a partial and reversible attenuation of the GH response to hexarelin".16 Total body fat, lean body mass and bone mineral density did not change (P = 0.6, 0.3 and 0.3), and of the bone markers only C-terminal propeptide of type I collagen was higher at week 16 (P = 0.019).16 In the 1999 report on the same dose and length, the cortisol area fell from 1506 ± 77 nmol/l/h at baseline to 1222 ± 92 at week 16 (P < 0.05) and was 1586 ± 58 at week 20, and urinary free cortisol and the ACTH and prolactin areas did not change significantly.24 The PubMed records name no sponsor.

Deeper analysis: intranasal hexarelin in short children

In 8 prepubertal short children given intranasal hexarelin for up to 8 months, Laron and colleagues described the effects as achieved "seemingly without undesirable side-effects".17 Skinfold thickness decreased despite an increase in body weight, head circumference increased, serum phosphate rose from 1.5 ± 0.1 to 1.8 ± 0.1 mmol/l (P < 0.004) and alkaline phosphatase from 219 ± 74 to 261 ± 75 U/l (P < 0.05).17 Klinger, Laron and colleagues at Tel Aviv University used the same dose in 7 children for 6 to 10 months.18 The peak GH response to an intranasal test dose fell from 70.6 ± 28.2 to 34.1 ± 15.7 mU/l after 7 days (P < 0.002) and stood at 37.5 ± 10.3 after 6 months of treatment, the response to an intravenous test dose fell from 84.8 ± 52.5 before treatment to 19.8 ± 10.9 at the end of the treatment period (P < 0.05), and three months after treatment stopped the intranasal response rose to 42.1 ± 4.7 (P < 0.005).18 The authors wrote that the "partial suppression of pituitary hGH responsiveness to long-term intranasal hexarelin treatment, probably due to desensitization, does not affect the observed increase in growth velocity".18 Neither PubMed record describes a comparison group or names a sponsor.

Deeper analysis: hexarelin and left ventricular function

Bisi and colleagues in Turin gave intravenous hexarelin to 7 men with GH deficiency and 9 controls and measured LVEF by radionuclide angiocardiography.19 The GH response in the patients was negligible, yet LVEF rose in both groups without changing catecholamine levels, mean blood pressure or cardiac output, and the authors concluded that hexarelin "exerts a short-lasting positive inotropic effect in humans, probably GH-independent".19 Imazio and colleagues found that LVEF did not change in 8 patients with dilated cardiomyopathy despite a similar GH rise, whereas it rose in 5 patients with ischemic cardiomyopathy.25 Broglio and colleagues, in patients having bypass surgery, reported rises in cardiac index, cardiac output and mean arterial pressure and wrote that the effect on cardiac performance "is not mediated by the increase in circulating GH levels but more likely reflects activation of specific cardiovascular GH secretagogue receptors".23 All three gave hexarelin acutely by the intravenous route; the PubMed records of Bisi and Imazio do not state the dose, and none of the three names a sponsor.

5

Doses reported in studies

Sources in this part

  1. 26Dominikowski et al., 2026
Table 5.1Doses reported in studies7 rows
SourceDose and routeFrequency and length
Ghigo and colleagues, 19941 and 2 micrograms/kg intravenous; 1.5 and 3 micrograms/kg subcutaneous; 20 micrograms/kg intranasal; 20 and 40 mg oralSingle doses
Maccario and colleagues, 20021.5 micrograms/kg, subcutaneousTwo or three times in 24 hours
Rahim and colleagues, 19981.5 micrograms/kg, subcutaneousTwice daily for 16 weeks
Laron and colleagues, 199560 micrograms/kg, intranasalThree times daily for up to 8 months
Ghigo and colleagues, 19961.25 mg (about 18 micrograms/kg) intranasal; 20 mg (about 300 micrograms/kg) oralThree times daily for 8 days (intranasal) or 15 days (oral)
Frieboes and colleagues, 20044 × 50 micrograms, route not stated in the PubMed recordAt 22.00, 23.00, 24.00 and 01.00 h, with nocturnal hormone profiles
Broglio and colleagues, 20022.0 micrograms/kg, intravenousAcute administration

The app lists a typical dose of 100 to 200 mcg a day; the studies above report doses per kilogram or as fixed amounts per administration, and none states a daily total of 100 to 200 micrograms. A 2026 review by Dominikowski and colleagues lists, for "bodybuilding-related forums", 100 to 200 micrograms subcutaneously 1 to 2 times a day, a figure from websites cited in the review and not from a study.26 The review states that these online protocols "are not evidence-based treatment strategies, MUST NOT be interpreted as clinically validated or safe", and the pages it cites for hexarelin are a Swolverine blog post and a Peptide Initiative protocol page.26

In the intranasal study in 8 short children, Laron and colleagues described the effects as achieved "seemingly without undesirable side-effects", and in the intranasal and oral studies in elderly people, Ghigo and colleagues wrote that treatment "did not induce any side effect".17,22 Hormone effects are reported in single-dose and repeated-dose studies: in 12 normal subjects, 2.0 micrograms/kg of intravenous hexarelin raised ACTH from 16.3 ± 7.2 to 32.4 ± 17.7 pg/mL and cortisol from 110.0 ± 31.6 to 135.9 ± 51.0 micrograms/L.27 In patients with GH deficiency, Loche and colleagues reported a slight but significant rise in cortisol in all except those with ACTH deficiency.7 In 10 children with familial short stature, Laron and colleagues reported that plasma TSH decreased during the intranasal test (P < 0.005) but remained in the normal range.15 After two or three daily subcutaneous injections for 24 hours, secretion of prolactin, ACTH and cortisol did not change, and an intravenous hexarelin test at the end of the day raised prolactin and abolished the ACTH and cortisol response.20 In a sleep study that compared hexarelin with placebo in 7 young volunteers, stage 4 sleep in the first half of the night and EEG delta power over the total night decreased, and the authors hypothesised that "sleep is impaired after hexarelin since the GHRH/corticotropin-releasing hormone (CRH) ratio is changed in favour of CRH".28 The 2018 review by Sigalos and Pastuszak states for the class of growth hormone secretagogues that "available studies indicate that GHSs are well tolerated, with some concern for increases in blood glucose because of decreases in insulin sensitivity".4

The app lists IGF-1, blood glucose and insulin as markers to monitor with hexarelin. IGF-I did not change significantly in the 16-week twice-daily study (P = 0.24), nor after 8 days of intranasal hexarelin in elderly people, nor after 1 day of two or three daily injections.16,22,20 IGF-I rose with 15 days of oral hexarelin in 7 elderly women (p < 0.03) and in 8 short children given intranasal hexarelin (P < 0.004).22,17 The summary texts of the hexarelin studies cited here do not report blood glucose or insulin results, and the glucose statement above comes from a review of the class.

8

Regulatory and anti-doping status

The WADA 2026 Prohibited List, in effect from 1 January 2026, names examorelin (hexarelin) in section S2.2.4 as an example of GH-releasing peptides (GHRPs).1 Class S2 is prohibited at all times, in and out of competition, and all prohibited substances in that class are non-specified substances.1 The 2026 review by Dominikowski and colleagues, which covers hexarelin, refers to "the absence of regulatory approval for physique- or performance-related indications" for the compounds it covers.26 The text of FDA's page on bulk drug substances for compounding that may present significant safety risks, read on 16 November 2026, does not contain the words hexarelin or examorelin, and neither does the TGA's page on importing, compounding and supplying unapproved peptide products.

The studies cited here report a GH half-life of about 55 minutes after intravenous hexarelin, and a human plasma half-life of hexarelin itself is not among the figures in their PubMed records.3 The longest treatment cited is 6 to 10 months of intranasal doses in 7 children (up to 8 months in Laron and colleagues), the longest in elderly people is 16 weeks of twice-daily injections, and the most recent human study cited was published in 2004.18,17,16,28 The 2026 review by Dominikowski and colleagues states that "evidence for downstream anabolic or body-composition–related effects of hexarelin in humans is limited and largely derived from its capacity to increase GH and IGF-1".26 Sigalos and Pastuszak write for the class that "the safety of these compounds with long-term use, including evaluation of cancer incidence and mortality, is needed".4 Deaths and discontinuations are not reported in the PubMed records of the studies cited here, and the record of Imbimbo and colleagues is cut off at 250 words.

What is the half-life of hexarelin?

The app lists the half-life of hexarelin as about 1 hour. In 12 men given intravenous hexarelin, plasma GH fell to baseline within 240 min "with a half-life of about 55 min", which is the half-life of the GH response, and in dogs hexarelin's own terminal half-life was 120 min.3,12

What is hexarelin?

Hexarelin is a synthetic hexapeptide that stimulates the release of growth hormone and is also named examorelin.3,1

Is hexarelin banned by WADA?

The WADA 2026 Prohibited List names examorelin (hexarelin) in section S2.2.4 as an example of GH-releasing peptides.1 Class S2 is prohibited at all times, in and out of competition.1

Does hexarelin have a regulatory approval?

A 2026 review by Dominikowski and colleagues that covers hexarelin refers to "the absence of regulatory approval for physique- or performance-related indications" for the compounds it covers.26 ClinicalTrials.gov returned 0 studies for hexarelin on 16 November 2026. None of the cited sources states whether any regulator has approved hexarelin for another indication.

What is the bioavailability of hexarelin?

The app lists the bioavailability of subcutaneous hexarelin as 95%. Ghigo and colleagues estimated from GH levels 77.0 ± 10.5% subcutaneous, 4.8 ± 0.9% intranasal and 0.3 ± 0.1% oral, and in rats subcutaneous bioavailability was 64%.2,14,13

Does the GH response to hexarelin fall with repeated use?

In 12 healthy elderly people given 1.5 micrograms/kg twice daily for 16 weeks, GH area under the curve fell from 19.1 ± 2.4 to 10.5 ± 1.8 micrograms/L.h, which the authors called partial and reversible.16,21 In 7 short children given intranasal hexarelin, the peak GH response to a test dose fell from 70.6 ± 28.2 to 34.1 ± 15.7 mU/l after 7 days.18 Ghigo and colleagues reported that 8 days of intranasal and 15 days of oral hexarelin, three times daily in 7 and 7 elderly people, did not desensitize the GH response.22

What side effects of hexarelin are reported in studies?

Single intravenous doses raised ACTH, cortisol and prolactin, and 4 × 50 micrograms at 22.00, 23.00, 24.00 and 01.00 h decreased stage 4 sleep in the first half of the night.27,5,28 Laron and colleagues described intranasal treatment in children as "seemingly without undesirable side-effects", and Ghigo and colleagues wrote that intranasal and oral treatment in elderly people "did not induce any side effect".17,22

How does hexarelin compare with GHRP-2 and GHRP-6?

In 6 normal young adults, 1 and 2 micrograms/kg of intravenous GHRP-2 and hexarelin gave a similar GH response.8 The introduction of a 2004 sleep study states that "hexarelin is superior to GHRH and GHRP-6 in stimulating GH release"; the study itself compared hexarelin with placebo.28

What did hexarelin do to the heart in human studies?

Acute intravenous doses raised LVEF in 7 men with GH deficiency, 9 controls, 5 patients with ischemic cardiomyopathy and patients in a 24-patient four-arm bypass surgery study (hexarelin group size not stated), and did not change it in 8 patients with dilated cardiomyopathy.19,25,23

12

References

  1. World Anti-Doping Agency. World Anti-Doping Code International Standard Prohibited List 2026. In effect 1 January 2026. WADA 2026 list
  2. Ghigo E, et al. Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man. J Clin Endocrinol Metab 1994. PMID 8126144
  3. Imbimbo BP, et al. Growth hormone-releasing activity of hexarelin in humans. A dose-response study. Eur J Clin Pharmacol 1994. PMID 7957536
  4. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev 2018. PMID 28400207
  5. Massoud AF, Hindmarsh PC, Brook CG. Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study. J Clin Endocrinol Metab 1996. PMID 8954038
  6. Massoud AF, et al. The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity. Clin Endocrinol (Oxf) 1996. PMID 8762732
  7. Loche S, et al. The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency. J Clin Endocrinol Metab 1995. PMID 7673411
  8. Arvat E, et al. Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH. Peptides 1997. PMID 9285939
  9. Mao Y, Tokudome T, Kishimoto I. The cardiovascular action of hexarelin. J Geriatr Cardiol 2014. PMID 25278975
  10. Bodart V, et al. CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res 2002. PMID 11988484
  11. Orkin RD, et al. Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro. J Endocrinol Invest 2003. PMID 14669829
  12. Roumi M, et al. Radioimmunoassay for hexarelin, a peptidic growth hormone secretagogue, and its pharmacokinetic studies. Peptides 1995. PMID 8545255
  13. Roumi M, et al. Kinetics and disposition of hexarelin, a peptidic growth hormone secretagogue, in rats. Drug Metab Dispos 2000. PMID 10611139
  14. Westberg C, et al. Hexarelin--evaluation of factors influencing oral bioavailability and ways to improve absorption. J Pharm Pharmacol 2001. PMID 11578108
  15. Laron Z, et al. Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin). Clin Endocrinol (Oxf) 1994. PMID 7955465
  16. Rahim A, O'Neill PA, Shalet SM. Growth hormone status during long-term hexarelin therapy. J Clin Endocrinol Metab 1998. PMID 9589671
  17. Laron Z, et al. Intranasal administration of the GHRP hexarelin accelerates growth in short children. Clin Endocrinol (Oxf) 1995. PMID 8548949
  18. Klinger B, et al. Desensitization from long-term intranasal treatment with hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children. Eur J Endocrinol 1996. PMID 8766941
  19. Bisi G, et al. Cardiac effects of hexarelin in hypopituitary adults. Eur J Pharmacol 1999. PMID 10528131
  20. Maccario M, et al. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans. Eur J Endocrinol 2002. PMID 11888836
  21. Rahim A, Shalet SM. Does desensitization to hexarelin occur? Growth Horm IGF Res 1998. PMID 10990150
  22. Ghigo E, et al. Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. Eur J Endocrinol 1996. PMID 8921821
  23. Broglio F, et al. Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery. Eur J Pharmacol 2002. PMID 12144941
  24. Rahim A, O'Neill PA, Shalet SM. The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin. Clin Endocrinol (Oxf) 1999. PMID 10341859
  25. Imazio M, et al. GH-independent cardiotropic activities of hexarelin in patients with severe left ventricular dysfunction due to dilated and ischemic cardiomyopathy. Eur J Heart Fail 2002. PMID 11959048
  26. Dominikowski A, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne) 2026. PMC13322892
  27. Ghigo E, et al. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab 1997. PMID 9253314
  28. Frieboes RM, et al. Hexarelin decreases slow-wave sleep and stimulates the secretion of GH, ACTH, cortisol and prolactin during sleep in healthy volunteers. Psychoneuroendocrinology 2004. PMID 15177700